Science & health
UK authorizes quarterly plozasiran injections for a rare lipid disorder
The UK Medicines and Healthcare products Regulatory Agency authorized plozasiran, marketed as Redemplo, for adults with familial chylomicronaemia syndrome alongside a low-fat diet. The quarterly injection targets a liver protein involved in triglyceride breakdown. In the main 75-person study, triglycerides fell by about 80% after 10 months among treated participants, compared with 17% for placebo, and fewer acute pancreatitis episodes were recorded. Raised blood sugar was the most common reported side effect. The authorization was granted to Arrowhead Pharmaceuticals Ireland.
Editorial summary · Publisher article
What matters
- Plozasiran is administered as a 25 mg injection once every three months after patient or caregiver training.
- The main study included 50 treated participants and 25 receiving placebo.
- The regulator reported fewer acute pancreatitis episodes among treated participants.
- Hyperglycaemia may affect more than one in 10 people; headache, nausea, and injection-site reactions were also reported.
Context & caveats
- The supplied evidence reports regulatory and trial results but does not provide long-term safety data or independent clinical interpretation.
Why this made the edition
The UK medicines regulator provides a specific authorization, treatment population, dosing schedule, trial size, comparative triglyceride results, pancreatitis findings, and adverse effects. The evidence is a first-party regulatory announcement, so the report should preserve that provenance.
Source material